Ticagrelor Drug Profile

What is Ticagrelor?

Ticagrelor is an antiplatelet medication that belongs to a class of drugs called P2Y12 receptor antagonists. It is primarily used to prevent blood clots in patients with acute coronary syndrome or those who have undergone coronary stent procedures. This medication helps reduce the risk of heart attack, stroke, and cardiovascular death by preventing platelets from clumping together to form dangerous clots.

Uses

Ticagrelor is approved for several cardiovascular conditions:

• Acute coronary syndrome: Used with aspirin to reduce the risk of cardiovascular death, heart attack, and stroke in patients with unstable angina or heart attack
• Post-stent placement: Prevents clot formation in patients who have received coronary artery stents during percutaneous coronary intervention
• Secondary prevention: Reduces risk of recurrent cardiovascular events in patients with established coronary artery disease
• Stroke prevention: May be used to prevent stroke in certain high-risk patients with a history of stroke or transient ischemic attack
• Peripheral artery disease: Sometimes prescribed to reduce cardiovascular events in patients with symptomatic peripheral artery disease

How it works

Ticagrelor works by blocking P2Y12 receptors on platelets, which are blood cells responsible for clotting. When these receptors are blocked, platelets cannot receive signals that would normally cause them to stick together and form clots. Unlike some other antiplatelet drugs, ticagrelor binds reversibly to these receptors, meaning its effects gradually wear off when the medication is stopped.

Side effects

Common side effects include:

Submit Your Paper

• Shortness of breath (dyspnea)
• Easy bruising
• Minor bleeding or prolonged bleeding from cuts
• Nosebleeds
• Dizziness
• Headache
• Nausea
• Fatigue

Serious side effects to watch for:

• Severe or uncontrolled bleeding
• Signs of internal bleeding (black or bloody stools, vomiting blood)
• Severe shortness of breath that doesn’t improve
• Signs of stroke (sudden weakness, confusion, vision problems)
• Severe allergic reactions (rash, swelling, difficulty breathing)

Warnings and precautions

• Bleeding risk: Patients with active bleeding, history of intracranial hemorrhage, or severe liver disease should not use ticagrelor due to increased bleeding risk
• Surgery considerations: Must be discontinued before elective surgery due to bleeding risk; timing depends on the procedure and should be determined by healthcare providers
• Pregnancy and breastfeeding: Limited safety data available; should only be used when potential benefits outweigh risks and under close medical supervision
• Kidney function: While dose adjustment may not be necessary for mild kidney impairment, patients with severe kidney disease require careful monitoring
• Respiratory conditions: Use with caution in patients with asthma or chronic obstructive pulmonary disease due to potential breathing difficulties

Interactions

Ticagrelor has several important drug interactions:

• Strong CYP3A inhibitors (ketoconazole, clarithromycin): Can increase ticagrelor levels and bleeding risk
• Strong CYP3A inducers (rifampin, phenytoin): May reduce ticagrelor effectiveness
• Warfarin and other anticoagulants: Significantly increases bleeding risk when used together
• High-dose aspirin (more than 100mg daily): May reduce ticagrelor’s effectiveness
• Digoxin: Ticagrelor can increase digoxin levels, requiring monitoring
• Simvastatin and lovastatin: Ticagrelor may increase levels of these cholesterol medications
• NSAIDs (ibuprofen, naproxen): Increases bleeding risk
• St. John’s Wort: This herbal supplement may reduce ticagrelor effectiveness

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosing for ticagrelor varies by indication. For acute coronary syndrome, the usual regimen is a 180mg loading dose followed by 90mg twice daily, taken with low-dose aspirin (75-100mg daily). For long-term secondary prevention, a lower maintenance dose of 60mg twice daily may be used. Tablets should be taken at the same times each day and can be taken with or without food. Patients should not stop taking ticagrelor suddenly without consulting their healthcare provider, as this may increase the risk of cardiovascular events. Dosage adjustments may be necessary based on individual patient factors, medical history, and response to treatment, and should always be determined by a qualified healthcare provider.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).